Balaji Gandhi Sells 28,759 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 28,759 shares of Phreesia stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $30.00, for a total transaction of $862,770.00. Following the completion of the sale, the chief financial officer now directly owns 116,174 shares in the company, valued at approximately $3,485,220. The trade was a 19.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, February 18th, Balaji Gandhi sold 5,771 shares of Phreesia stock. The shares were sold at an average price of $30.04, for a total transaction of $173,360.84.
• On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The shares were sold at an average price of $27.48, for a total transaction of $132,261.24.
• On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The shares were sold at an average price of $27.31, for a total transaction of $159,135.37.
• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total transaction of $22,555.28.
• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total transaction of $85,018.95.

Phreesia Stock Performance

Shares of PHR opened at $28.49 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.66 billion, a P/E ratio of -19.38 and a beta of 0.96. The company has a 50-day moving average of $27.22 and a two-hundred day moving average of $23.80. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.58) earnings per share. As a group, research analysts predict that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Truist Financial raised their price objective on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Citigroup raised their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. JMP Securities reiterated a “market outperform” rating and issued a $30.00 price objective on shares of Phreesia in a research note on Tuesday, December 10th. Finally, KeyCorp raised their price objective on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, January 8th. Thirteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Phreesia currently has a consensus rating of “Buy” and a consensus price target of $31.15.

Institutional Investors Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently modified their holdings of the company. PharVision Advisers LLC purchased a new stake in shares of Phreesia during the fourth quarter worth about $302,000. Two Sigma Advisers LP purchased a new stake in shares of Phreesia during the fourth quarter worth about $302,000. Silvercrest Asset Management Group LLC grew its holdings in shares of Phreesia by 31.0% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 394,352 shares of the company’s stock worth $9,922,000 after buying an additional 93,349 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Phreesia by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 15,585 shares of the company’s stock worth $392,000 after buying an additional 5,127 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in shares of Phreesia by 77.1% during the fourth quarter. Nuveen Asset Management LLC now owns 235,827 shares of the company’s stock worth $5,933,000 after buying an additional 102,662 shares in the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.